15222-B Avenue of Science
59 articles with DermTech International
DermTech, Inc., the global leader in non-invasive molecular dermatology, announced today the appointment of Dr. Stevan Knezevich to its Scientific Advisory Board.
DermTech, Inc., the global leader in non-invasive molecular dermatology, announced today the presentation of a clinical research abstract at the 37th Annual Fall Clinical Dermatology Conference in Las Vegas, Nevada.
DermTech, Inc., the global leader in non-invasive molecular dermatology, announced today the publication of “Non-Invasive Gene Expression Testing to Rule Out Melanoma,” by Dr. Jason Rivers of the Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada, and colleagues in Skin Therapy Letter.
DermTech, Inc. announced today it has completed enrollment in a clinical study to assess DNA damage induced by an excimer laser and evaluate the potential of topical agents T4 endonuclease and photolyase to reduce DNA damage induced as measured through gene expression analysis.
DermTech, Inc. announced the publication of “Real-world performance and utility of a noninvasive gene expression assay to evaluate melanoma risk in pigmented lesions,” by Dr. Laura Ferris of the University of Pittsburgh, et al, in Melanoma Research.
DermTech Announces the Publication of a Health Economic and Utility Study of the PLA in JAMA Dermatology
DermTech, Inc. announced the publication of “Economic Implications of a Non-Invasive Molecular Pathology Assay for Pigmented Skin Lesions” by John Hornberger MD and Daniel M. Siegel MD in JAMA Dermatology.
DermTech, Inc. announced it has initiated enrollment in a clinical study to assess DNA damage induced by an excimer laser and evaluate the potential of T4 endonuclease topical DNA repair enzyme and photolyase cream
DermTech, Inc., the global leader in non-invasive molecular dermatology, announced today the publication of two clinical study abstracts at the 2018 International Investigational Dermatology meeting in Orlando, Fl.
DermTech, Inc., the global leader in non-invasive molecular dermatology, announced completion of enrollment in the Carcinome™ clinical study.
Cindy is a recognized leader in diagnostics, life sciences, and therapeutics. Prior to her most recent position as CEO of Human Longevity Inc.
DermTech, Inc. announced it is partnering with the Melanoma Research Foundation in support of five Miles for Melanoma Run/Walks held throughout the US, kicking off this month during Melanoma Awareness Month.
DermTech’s Late Breaking Abstract Presented at AAD Validates Gene Expression Against High Risk DNA Mutations Providing Objective Information for the Diagnosis of Melanoma
The data provides the foundation for launching Nevome, DermTech’s second “adhesive patch skin biopsy” product, to help assess pigmented lesions suspicious for melanoma.
Provincial coverage approvals are in process, initially focused on British Columbia and Ontario, and are expected to expand across Canada.
The PLA tool helped the dermatologist to correctly diagnose melanoma in a patient who was reluctant to receive a surgical biopsy.
He is world-renown for his work in dermoscopy and confocal microscopy.
DermTech, Inc. announced today the appointment of Daniel M. Siegel, MD, to its Scientific Advisory Board. Dr. Siegel is a Clinical Professor of Dermatology and former Director of the Procedural Dermatology Fellowship at SUNY Downstate.